Sutton G P, Bundy B N, Omura G A, Yordan E L, Beecham J B, Bonfiglio T
Department of Obstetrics and Gynecology, Indiana University Medical School, Indianapolis 46227.
Gynecol Oncol. 1991 Jun;41(3):230-3. doi: 10.1016/0090-8258(91)90314-u.
By serendipity we have had the opportunity to evaluate cis-platin-based chemotherapy in ovarian tumors of low malignant potential (LMP). Optimal (less than 1 cm residual disease) FIGO stage III ovarian carcinomas were randomly assigned to treatment with cisplatin plus cyclophosphamide with or without doxorubicin on a prospective Gynecologic Oncology Group Study. On review by the Gynecologic Oncology Group Pathology Committee, 32 of these cases were determined to represent low malignant potential tumors. Mean age of patients with these lesions was 48 years (range, 25-75 years). After initial cytoreduction, 19 patients had residual disease less than 1 cm and 13 had no residual. Twenty (62.5%) received cisplatin plus cyclophosphamide and 12 cisplatin, cyclophosphamide, and doxorubicin chemotherapy; 75% of patients received six or more courses. Second-look surgery was done in 15 cases; only six were negative. However, with a median follow-up of 31.7 months (range, 1-75), only 1 patient has died; no cancer was found at autopsy. The remaining patients are alive without clinical evidence of disease at a median of 30 months. The need for adjunctive therapy in patients with advanced LMP tumors remains speculative.
机缘巧合之下，我们有机会评估基于顺铂的化疗对低恶性潜能（LMP）卵巢肿瘤的疗效。在一项前瞻性妇科肿瘤学组研究中，国际妇产科联盟（FIGO）分期为III期的最佳（残留病灶小于1 cm）卵巢癌被随机分配接受顺铂加环磷酰胺治疗，部分患者联合或不联合阿霉素。经妇科肿瘤学组病理委员会复查，这些病例中有32例被确定为低恶性潜能肿瘤。这些病灶患者的平均年龄为48岁（范围25 - 75岁）。初始细胞减灭术后，19例患者残留病灶小于1 cm，13例无残留。20例（62.5%）接受顺铂加环磷酰胺治疗，12例接受顺铂、环磷酰胺和阿霉素化疗；75%的患者接受了六个或更多疗程的治疗。15例患者进行了二次探查手术；仅6例结果为阴性。然而，中位随访31.7个月（范围1 - 75个月），仅1例患者死亡；尸检未发现癌症。其余患者存活，在中位30个月时无疾病的临床证据。对于晚期LMP肿瘤患者是否需要辅助治疗仍存在推测。
